News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Zeltia Group Says Yondelis on Track, Delays Neuropharma Unit IPO
March 6, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MADRID, March 6 (Reuters) - Spanish pharmaceuticals firm Zeltia said on Thursday anti-cancer drug Yondelis was meeting forecasts but said the listing of its Neuropharma unit would be delayed because of poor markets.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Europe
MORE ON THIS TOPIC
Rare diseases
Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
August 13, 2026
·
2 min read
·
Tristan Manalac
Bankruptcy
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
August 13, 2026
·
2 min read
·
Tristan Manalac
Insights
The Italian inflection point: Clinical strength, culture and capital
August 13, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Business
Behind the bell: Gearing up to go public
August 13, 2026
·
6 min read
·
Angela Gabriel
